Evaluation of Adverse Drug Events in Patients on Anti-Retroviral Therapy Regimen at Omdurman Voluntary Counselling and Testing and Anti-Retroviral Therapy Center in Sudan – A Cross-Sectional Study

References

• Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799. doi:10.1212/01.WNL.0000287431.88658.8b
   PubMed Web of Science ®Google Scholar
• Jeudason T. Global progress reported for AIDS. Lancet Infect Dis. 2023;23(9).
   Web of Science ®Google Scholar
• Ismail SM, Kari F, Kamarulzaman A. The socioeconomic implications among people living with HIV/AIDS in Sudan: challenges and coping strategies. J Int Assoc Provid AIDS Care. 2017;16(5):446–454. doi:10.1177/2325957415622449
   PubMedGoogle Scholar
• Sudan National AIDS Council. Sudan National Plan and Sectoral Plans on HIV/AIDS. 2009. 1–49 p.
   Google Scholar
• UNAIDS. UNAIDS 2023 Reference; 2023:1–463.
   Google Scholar
• Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV TREATMENT-CLINICAL POINTS OF VIEW AND PRACTICAL CONSIDERATIOns. Front Pharmacol. 2017;8(831). doi:10.3389/fphar.2017.00831
   PubMedGoogle Scholar
• Reddy TM, Ts DP, Reddy SG, et al. A pharmacovigilance study of antiretroviral therapy in HIV positive out patients at a tertiary care teaching hospital. Int J Basic Clin Pharmacol. 2018;7(12):2419–2422. doi:10.18203/2319-2003.ijbcp20184858
   Google Scholar
• Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care. 2013;25(4):400–414. doi:10.1080/09540121.2012.712667
   PubMed Web of Science ®Google Scholar
• Rukmangathen R, Brahmanapalli VD, Thammisetty DP, Pemmasani D, Gali SP, Atmakuru RB. Study of adverse drug reactions to antiretroviral therapy in a tertiary care hospital, Tirupati. Perspect Clin Res. 2020;11(4):158–163. doi:10.4103/picr.PICR_133_18
   PubMedGoogle Scholar
• Oumar AA, Abdoulaye A, Maiga M, et al. Adverse drug reactions to antiretroviral therapy (ART): prospective study in HIV infected adults in sikasso (Mali). J Pharmacovigil. 2017;5(2):1–7. doi:10.4172/2329-6887.1000228
   Google Scholar
• Elnagar BMI. Prevalence and Extent of Adverse Drug Reactions in Sudanese Patients in Highly Active Anti-retroviral Therapy Regimens. Int J Pharmacovigil. 2017;2(2):1–12. doi:10.15226/2476-2431/2/2/00118
   Google Scholar
• Popoola TD, Awodele O, Oshikoya KA. A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Afr J med Sci. 2016;45:179–187.
   Google Scholar
• Sarfo FS, Sarfo MA, Chadwick D. Incidence and risk factors for neuropsychiatric events among Ghanaian HIV patients on long-term non-nucleoside reverse transcriptase inhibitor-based therapy. eNeurologicalSci. 2016;3:21–25. doi:10.1016/j.ensci.2015.12.002
   PubMedGoogle Scholar
• Achappa B, Madi D, Bhaskaran U, Ramapuram JT, Rao S, Mahalingam S. Adherence to antiretroviral therapy among people living with HIV. N Am J Med Sci. 2013;5(3):220–223. doi:10.4103/1947-2714.109196
   PubMedGoogle Scholar
• Azevedo LN, Ximenes RA DA, Monteiro P, Montarroyos UR, Miranda-Filho D DB. Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS. Brazilian J Infect Dis. 2020;24(1):65–72. doi:10.1016/j.bjid.2019.11.002
   PubMed Web of Science ®Google Scholar
• Prosperi MC, Fabbiani M, Fanti I, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012;12:1–11. doi:10.1186/1471-2334-12-296
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. World Health; 2004. Available from: http://pvtoolkit.org/toolkit/readers/pv_ensuring_safe_medicine_use.pdf. Accessed April 16, 2024.
   Google Scholar
• WHO. A practical handbook on the pharmacovigilance of antiretroviral medicines. WHO press, World Health Organization; 2009. Available from: http://apps.who.int/medicinedocs/documents/s16882e/s16882e.pdf. Accessed April 16, 2024
   Google Scholar
• Fina PM, Cunningham FE, Zhao X, et al. Reporting of adverse drug events in the veterans health administration for patients whose treatment with empagliflozin or apixaban was discontinued. Am J Heal Pharm. 2020;77(1):22–32. doi:10.1093/ajhp/zxz261
   PubMed Web of Science ®Google Scholar
• Slovin E Slovin’s formula for sampling technique; 1960.
   Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Star K, Sandberg L, Bergvall T, Choonara I, Caduff-Janosa P, Edwards IR. Paediatric safety signals identified in VigiBase: Methods and results from Uppsala monitoring centre. Pharmacoepidemiol Drug Saf. 2019;28(5):680–689. doi:10.1002/pds.4734
   PubMed Web of Science ®Google Scholar
• de Los Rios P, Okoli C, Punekar Y, et al. Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. Prev Med. 2020;139(106182):25. doi:10.1016/j.ypmed.2020.106182
   Google Scholar
• Sendaula E, Buwembo M, Opio D. Clinical profile of HIV-infected adults receiving a holistic approach of care model in Nakawa. Kampala Dis PLoS One. 2022;17(7):1–8. doi:10.1371/journal.pone.0272039
   Web of Science ®Google Scholar
• Solomon FB, Angore BN, Koyra HC, Tufa EG, Berheto TM, Admasu M. Spectrum of opportunistic infections and associated factors among people living with HIV/AIDS in the era of highly active anti-retroviral treatment in Dawro Zone hospital: a retrospective study. BMC Res Notes. 2018;11(1):1–7. doi:10.1186/s13104-018-3707-9
   PubMedGoogle Scholar
• Hassan RHA, Abdelaal AA, Mohammed HA, Elbashir MA, Khalid KB. Survival and mortality analysis for HIV patients in Khartoum State, Sudan 2017. World J Public Heal. 2018;3(4):118–124.
   Google Scholar
• UNDP. HIV-related stigma and discrimination In Asia: a review of human development consequences; 2007.
   Google Scholar
• UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. UNAIDS; 2014.
   Google Scholar
• Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA Panel. JAMA. 2020;324(16):1651–1669. doi:10.1001/jama.2020.17025
   PubMed Web of Science ®Google Scholar
• Koochak HE, Babaii A, Pourdast A, et al. Prevalence of adverse drug reactions to highly active antiretroviral therapy (HAART) among HIV Positive patients in imam Khomeini hospital of Tehran, Iran. Infect Disord Drug Targ. 2017;17(2):116–119. doi:10.2174/1871526517666170117111350
   PubMedGoogle Scholar
• Sudan National AIDS Control Programme. Global AIDS response progress reporting 2012-2013; 2014.
   Google Scholar
• Onoya D, Hirasen K, van den Berg L, Miot J, Long LC, Fox MP. Adverse drug reactions among patients initiating second-line antiretroviral therapy in South Africa. Adis. 2018;41:1343–1353. doi:10.1007/s40264-018-0698-3
   Google Scholar
• Agu K, Oparah A, Ochei U. Knowledge and attitudes of HIV-infected patients on antiretroviral therapy regarding adverse drug reactions (ADRs) in selected hospitals in Nigeria. Perspect Clin Res. 2012;3(3):95. doi:10.4103/2229-3485.100657
   PubMedGoogle Scholar